Two Roads Diverge For Mylan: Teva Or Perrigo
This article was originally published in The Tan Sheet
Executive Summary
Teva announced a proposal to acquire Mylan for $82 per share, or roughly $40 billion, putting Mylan’s independence and a proposal to acquire OTC drug specialist Perrigo in question. Adding to the uncertainty, Perrigo rejected Mylan’s offer after market close.
You may also be interested in...
Teva Changes Its Tune On Substitutable Generic Advair
Teva is aggressively developing a fully substitutable generic version of Advair and other AB-rated respiratory products now that FDA has released draft guidance on bioequivalence requirements for the inhaled respiratory drug.
Japan Grants Global-First Approval To Zolbetuximab, 15 Other New Drugs
Astellas's first-in class CLDN18.2-targeting antibody receives its first approval worldwide, while crovalimab and a number of drugs for rare diseases also receive nods from regulators and are now awaiting reimbursement price-listing.
Hanmi-OCI Merger Hits Wall As Brothers Win Shareholder Vote, Board Seats
The planned merger of Korea's Hanmi Pharm Group with OCI Group hits a major speed bump as the two sons of Hanmi's founder and other candidates recommended by them secture board seats. But it remains to be seen how the Lim brothers will fulfil their ambitious promises.